Navigation Links
Bioniche Converts a Portion of its Debt to Equity
Date:3/27/2008

- results in US$1.75 million of new available funds -

BELLEVILLE, ON, March 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the Company has exercised its right under the agreement to repay US$1.75 million of its secured revolving credit facility with Valens U.S. (formerly Laurus Master Funds) in common shares.

The conversion is in accordance with the formula set out in the original agreement signed in 2005. The shares will be priced at the ten day market average less 15% which equates to 2,671,900 shares. In addition, the Company will issue 200,000 five-year warrants at market price ($0.77 per share) in exchange for Valens waiving certain volume restrictions relating to the conversion under the agreement. There is no penalty attached to this repayment.

This conversion will result in new available funds of US$1.75 million. As a result, the Company's capacity to borrow under the revolving credit facility after the conversion will be approximately US$3.2M, determined by a formula which measures existing levels of inventory and accounts receivable.

"Again we appreciate the support and flexibility of our bankers, Valens U.S.," said Patrick Montpetit, Chief Financial Officer of Bioniche Life Sciences Inc. "This private placement will improve our liquidity as we continue to execute our Phase III clinical development program with Urocidin in bladder cancer and begin the construction of a facility in which to scale-up production of our E. coli O157:H7 cattle vaccine in Belleville, Ontario."

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximatel
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
2. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
3. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
4. Bioniche Reports Fiscal 2008 Second Quarter
5. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
6. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
7. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
8. Bioniche Reports Fiscal 2008 First Quarter
9. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
10. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
11. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 1ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 2ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 3ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 4Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 1Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 2Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 3Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 1Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 2Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 3
Other Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 2Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 3Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 5Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 6Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 7Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 8Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 9